GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Chen, Melissa ^a   Angeli, Franca S ^a   Shen, You tang ^a   Shannon, Richard P ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aging; Dilated cardiomyopathy; Glucagon like pepetide 1; Myocardial insulin resistance

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; MYOCARDIAL INSULIN; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; PEPTIDE FRAGMENT;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEAGLE; CARDIOVASCULAR MORTALITY; CELL ISOLATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY FLOW RESERVE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE PREDISPOSITION; FATTY ACID BLOOD LEVEL; GLUCOSE TRANSPORT; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE BIOPSY; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEAN ARTERIAL PRESSURE; NONHUMAN; PROPHYLAXIS; RELAXATION TIME; SENESCENCE; ANIMAL; BLOOD; DOG; DRUG EFFECTS; HEART MUSCLE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION;

AGING; ANIMALS; CARDIOTONIC AGENTS; DISEASE PROGRESSION; DOGS; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; MYOCARDIUM; PEPTIDE FRAGMENTS; RANDOM ALLOCATION;

EID: 84905996864     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0115-x     Document Type: Article

References (36)

1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993, 22:6A-13A. 8376698.
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993, 88:107-115. 8319323.
3. Oxenham H, Sharpe N. Cardiovascular aging and heart failure. Eur J Heart Fail 2003, 5:427-434. 12921803.
4. Bhashyam S, Parikh P, Bolukoglu H, Shannon AH, Porter JH, Shen YT, Shannon RP. Aging is associated with myocardial insulin resistance and mitochondrial dysfunction. Am J Physiol Heart Circ Physiol 2007, 293:H3063-H3071. 17873028.
5. Torlinska T, Mackowiak P, Nogowski L, Hryniewiecki T, Witmanowski H, Perz M, Md E, Nowak KW. Age dependent changes of insulin receptors in rat tissues. J Physiol Pharmacol 2000, 51:871-881. 11220495.
6. Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R. Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 2007, 116:901-909. 17679614.
7. Di Lisa F, Bernardi P. Mitochondrial function and myocardial aging: a critical analysis of the role of permeability transition. Cardiovasc Res 2005, 66:222-232. 15820191.
8. Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Biochem 1997, 174:305-319. 9309704.
9. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Splegelman BM. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801. 12181572.
10. Anderson R, Prolla T. PGC-1alpha in aging and anti-aging interventions. Biochim Biophys Acta 2009, 1790:1059-1066. 19371772.
11. Loeb LA, Wallace DC, Martin GM. The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proc Natl Acad Sci U S A 2005, 102:18769-18770. 16365283.
12. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997, 45:968-974. 9256850.
13. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994, 266:E459-E466. 8166268.
14. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008, 478:136-142. 18708025.
15. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961. 15313949.
16. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007, 100:824-829. 17719327.
17. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177. 15582729.
18. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110:43-52. 12093887.
19. Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, Shannon RP. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010, 3:512-521. 20466848.
20. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004, 61:297-306. 14736546.
21. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005, 312:303-308. 15356213.
22. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005, 115:3587-3593. 16284649.
23. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979, 76:4350-4354. 388439.
24. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990, 186:407-421. 2233308.
25. Conley KE, Esselman PC, Jubrias SA, Cress ME, Inglin B, Mogadam C, Schoene RB. Ageing, muscle properties and maximal O(2) uptake rate in humans. J Physiol 2000, 526(Pt 1):211-217. 10878113.
26. Conley KE, Jubrias SA, Esselman PC. Oxidative capacity and ageing in human muscle. J Physiol 2000, 526(Pt 1):203-210. 10878112.
27. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142. 12750520.
28. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008, 88:581-609. 18391174.
29. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res 2011, 90:202-209. 21289012.
30. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol 2001, 33:1065-1089. 11444914.
31. Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2005, 2:85-93. 16098826.
32. Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol 2013, 12:154. 24148218.
33. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol 2013, 12:148. 24125539.
34. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326. 23992601.
35. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408. 16024574.
36. Galiatsatos P, Gibson BR, Rabiee A, Carlson O, Egan JM, Shannon RP, Andersen DK, Elahi D. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med 2014, 42:638-645. 24247476.